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Abstract 
Context: Therapeutic agents treating serious conditions are eligible for Food and Drug Administration 
(FDA) accelerated approval. The clinical evidence accrued on agents receiving accelerated approval has 
not been systematically evaluated.  Our objective was to assess the timing and characteristics of available 
studies.  
Methods: We first identified clinical studies of novel therapeutic agents receiving accelerated approval. 
We then (1) categorized those studies as randomized or non-randomized; (2) explored whether or not they 
evaluated the FDA-approved indications; and (3) documented the available treatment comparisons. We 
also meta-analyzed the difference in start times between randomized studies that (1) did or did not evaluate 
approved indications and (2) were or were not designed to evaluate the agent’s effectiveness.  
Findings: In total, 37 novel therapeutic agents received accelerated approval between 2000 and 2013. Our 
search identified 7,757 studies including 1,258,315 participants. Only one third of identified studies were 
randomized controlled trials. Of 1,631 randomized trials with advanced recruitment status, 906 were 
conducted in therapeutic areas for which agents received initial accelerated approval, 202 were in 
supplemental indications, and 523 were outside approved indications.  Only 411/906 (45.4%) trials were 
designed to test the effectiveness of agents that received accelerated approval (“evaluation” trials); others 
used these agents as common background treatment in both arms (“background” trials). There was no 
detectable lag between average start times of trials conducted within and outside initially approved 
indications. “Evaluation” trials started on average 1.52 years, (95% CI: 0.87 to 2.17) earlier than 
“background” trials.  
Conclusions: Cumulative evidence on agents with accelerated approvals has major limitations. Most 
clinical studies including these agents are small and non-randomized, and about a third are conducted in 
unapproved areas, typically concurrently with those conducted in approved areas. Most randomized trials 
including these therapeutic agents are not designed to evaluate directly their clinical benefits but 
incorporate them as standard treatment.   
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Policy points 
• Randomized trials – the gold standard of evaluating effectiveness – constitute a small minority of 
existing evidence on agents given accelerated approval; one third of randomized trials are in 
therapeutic areas outside of the FDA approval; and less than half evaluate the therapeutic benefits 
of these agents, but use them instead as common backbone treatments.  
• Agents receiving accelerated approval are often tested concurrently in several therapeutic areas.  
• For most agents, no substantial time lag is apparent between the average start dates of randomized 
trials evaluating their effectiveness and those using them as part of background therapies. 
• For most agents, no substantial time lag is apparent between the average start dates of randomized 
trials evaluating their effectiveness and those using them as part of background therapies. 
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Introduction 
The aim of biopharmaceutical regulation within the Food and Drug Administration (FDA) is to 
ensure that only effective and safe treatments reach patients.(1) FDA guidance suggests that manufacturers 
submit at least two well-controlled randomized clinical studies, each providing independent evidence of 
efficacy for their products.(2) The FDA reviews the clinical studies of investigational products and 
evaluates whether they are safe and effective in well-defined groups of patients before granting approval.  
Over the past three decades, the FDA has introduced significant flexibility to its evidence 
standards.(3) Regulators have created several programs aimed at expediting the approval of novel 
therapeutic agents that address unmet medical needs in the treatment of serious or life-threatening 
conditions.(4) For example, the “fast track” designation, created in 1988, permits approval of agents 
treating severely debilitating diseases after a single study.(5) Such expedited approval programs have 
become more common in recent years.(6) Over half of new agents entering the market benefit from 
expedited approval programs.   
 
FDA’s accelerated approval pathway 
In 1992, the United States Congress enacted the “accelerated approval” pathway.(1) Drugs and 
biologics expected to provide a meaningful advantage over available therapies for serious conditions have 
since been eligible for receiving accelerated FDA approval on the basis of surrogate measures.(7) Surrogate 
measures are proxies for clinically meaningful outcomes and are “reasonably likely” to predict clinical 
benefit. An oft-cited example of an established surrogate measure is the magnitude of cholesterol 
reduction, which has been demonstrated to predict the risk of future fatal and non-fatal heart attacks.(8) 
Such established surrogate measures are frequently used in regular FDA approvals.(9) However, many 
surrogate measures used for accelerated approval decisions are not established and have a weak empirical 
association with important outcomes such as overall survival.(10-12) Hence, agents granted accelerated 
approval on the basis of surrogate measures are required to conduct studies to confirm the anticipated 
clinical benefit.(5)   
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The objective of using surrogate measures as a basis for FDA accelerated approval is to reduce 
the evidence requirements and considerably shorten the duration of clinical testing required prior to 
market entry for agents targeting important conditions. The bar for market entry is therefore substantially 
lower for agents receiving accelerated vs. regular approval. Clinical studies used as the basis of regulatory 
decisions in the accelerated approval pathway are relatively small, have shorter follow-up durations, often 
lack comparators, and are less likely to be randomized.(13) Collectively, these study features effectively 
reduce the research and development timelines for agents in the accelerated approval pathway. According 
to a recent study, oncology agents receiving accelerated approval entered the market on average 4.7 years 
earlier than those receiving regular approval.(14)  
 
The need to compensate for the limitations of the available evidence on accelerated approval agents  
Therapeutic agents granted accelerated approval have premature data on their clinical benefits and 
harms at the time of market entry. Substantial research is thus needed to compensate for the limitations 
of the evidence base and generate meaningful, definitive data confirming clinical benefit following 
accelerated approval. However, FDA’s evidence standards for accelerated approval may influence 
evidence generation patterns not only for clinical studies aimed at regulatory approval, but also for the 
much larger numbers of studies conducted both before and after market entry.  
First, a low bar for initial market entry may have compounding effects on subsequent research 
activities, and facilitate clinical studies aimed at developing new uses. The industry may fragment and 
diversify its development activities and pursue research in several therapeutic areas in parallel and seek 
approval for supplemental indications.(15) Previous research has shown that regulatory requirements for 
supplemental indications are less arduous than those for original indications, potentially presenting an even 
lower bar for market entry than original accelerated approval. For example, clinical studies submitted for 
supplemental indications are less likely to have active comparators.(16) Regulatory review times for 
supplemental indication approvals are also shorter than those for original indications.(17) Pursuing 
research in several therapeutic areas in parallel is therefore a financially attractive strategy for the industry. 
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While there may be a scientific rationale for testing the efficacy of a new agent outside of its FDA-
approved indication, such decisions appear to be driven by commercial objectives; approximately 9 out of 
10 approvals for supplemental indications occur during the market exclusivity period.(18) Supplemental 
indications ultimately account for a substantial share of drug utilization, often surpassing the levels of use 
within the original indication.(19)  
Second, FDA’s approval of a novel therapeutic agent may be misinterpreted by the research 
community as regulatory backing for its immediate and widespread use as standard therapy.(20, 21) The 
agent granted accelerated approval may thus be used in trials of new drugs either as part of combination 
therapy or as a background treatment given to all patients. While there may be strong scientific rationale 
for evaluating the effectiveness of a new drug given in combination with an accelerated approval agent, 
such studies would not be able to generate evidence on the clinical benefits of the accelerated approval 
agent. Studies giving the accelerated approval agent to all patients would only be warranted after the clinical 
benefit of the accelerated approval agent has been established. If research evaluating the effectiveness of 
the accelerated approval agent is underway concurrently with research using it as background therapy, this 
may indicate that the research community has accepted it as an effective treatment option before valid 
evidence is available to confirm benefit. The speed with which accelerated approval drugs are tested in 
different combinations and as background therapy would thus be indicative of the strength of the 
regulatory signal sent to the research community with each accelerated approval decision.(22)  
 
Objectives 
To date, there has not been a systematic evaluation of the clinical evidence on agents receiving 
accelerated approval. Here, we explore the extent to which the objectives, nature and timing of research 
activity are aimed at addressing the limitations of the data available on agents receiving accelerated 
approval between 2000 and 2013. First, we document the total number of clinical studies, their sample 
size, and design characteristics. Second, we investigate the extent to which clinical evidence on novel 
therapeutic agents is generated in therapeutic areas for which FDA granted accelerated approval versus in 
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other indications. Third, we describe the types of available treatment comparisons in identified 
randomized controlled trials and determine whether these comparisons allow for evaluating the 
effectiveness of accelerated approval agents. We also examine the relative timing of randomized controlled 
trials done within vs. outside approved indications and those conducted for assessing effectiveness vs. 
background use of these agents.  
 
 
 
Methods 
Eligible agents  
We used the Drugs@FDA online database to identify the novel therapeutic agents (i.e., new 
molecular entities or novel biologic drugs) approved by the FDA.(23) Drugs@FDA includes drug 
approval and labeling decisions for all currently marketed prescription drugs and biologics. Using several 
publically available FDA documents(23, 24) in combination with Drugs@FDA, three investigators 
identified agents approved through the accelerated approval pathway between January 1, 2000, and 
December 31, 2013, and the indication(s) for which they were initially approved. Agents were included if 
they were categorized by the FDA as “S” (“surrogate”), which designates an approval that was based on 
a surrogate endpoint or an effect on a clinical endpoint other than survival or irreversible morbidity. We 
excluded 2 agents with “R” (“restricted”) designation, which indicates that an approval had restrictions to 
ensure safe use. If an agent received multiple approvals for different indications, doses, or routes of 
administration during this period, we only considered the initial approval (i.e., therapeutic agents that 
received accelerated approval in a supplemental indication were not eligible for inclusion). We confirmed 
the consistency of our selected sample with a published report on FDA approvals.(25)  
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Identification and categorization of clinical studies  
We screened Clinicaltrials.gov to identify the clinical studies of therapeutic agents receiving 
accelerated approval. Clinicaltrials.gov is a publicly available comprehensive clinical study registry and 
results database developed and maintained by the US National Library of Medicine.(26) It contains 
232,506 study records as of December 2016.(27)  
A data set comprising all registered clinical studies of eligible agents was downloaded from 
Clinicaltrials.gov on June 8, 2016. The data set included information on the following  
(1) disease or condition; 
(2) treatment comparator(s); 
(3) recruitment status (whether the study was still recruiting participants); 
(4) enrollment (sample size); 
(5) study design (whether treatments were randomly allocated); and 
(6) study start and end dates.  
Three investigators reviewed the clinical studies. Using predetermined criteria, we categorized each 
identified study according to its design, recruitment status, therapeutic area, and available treatment 
comparisons. As detailed below, we reviewed the identified studies in three levels. At the first level, we 
determined the proportion of available evidence that was generated in randomized controlled trials. 
Randomized controlled trials are considered to be the “gold standard” for establishing whether an 
investigational agent works or if it works better than another.(28) Decades of research have shown that 
non-randomized study designs (i.e., observational studies) are more likely to produce biased findings about 
the efficacy of a treatment.(29-31) 
Second, we identified the subset of randomized trials with advanced recruitment status and 
examined the proportion of available trials conducted in diseases or conditions with granted accelerated 
approval (i.e., FDA-approved indications). Finally, we examined the types of treatment comparisons 
available in randomized controlled trials conducted in initially approved indications.   
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Level 1: Study design 
Studies identified in Clinicaltrials.gov were considered to be randomized controlled trials if they 
randomly allocated participants into two or more treatment arms. All other designs were categorized as 
non-randomized studies. For each agent, we counted the number of randomized vs. non-randomized 
studies and the number of participants included.  
Among studies with randomized designs, we focused on studies with advanced recruitment status. 
We therefore excluded studies that were still recruiting participants and withdrawn studies. Consistent 
with a previous review of Clinicaltrials.gov,(32) studies were eligible for inclusion if they had any of the 
following recruitment designations: “active, not recruiting” (participants no longer enrolled, study may be 
ongoing); “completed” (trial ended normally); or “terminated” (trial was stopped early for any reason). We 
included “active, not recruiting” because investigators do not consistently update this designation after 
completing enrollment; many studies with published results have this listing. We also checked and 
confirmed that no studies that were still recruiting had results available in Clinicaltrials.gov.  
 
Level 2: Condition 
We determined whether randomized controlled trials were conducted within or outside of 
indications for which agents received accelerated approval, as identified using the Drugs@FDA database. 
Clinicaltrials.gov specifies for each study the primary disease or condition being evaluated according to 
the Medical Subject Headings (MeSH) controlled vocabulary used by the National Library of Medicine. 
We considered randomized controlled trials to be conducted outside of approved indications if done in 
patient populations with different diseases or conditions (e.g., multiple myeloma vs. lymphoma; colorectal 
carcinoma vs. head and neck cancer) to those specified in drug labels following initial accelerated approval 
or subsequent approval in new indications.(16) Our categorization was conservative: clinical studies in 
expanded patient populations (e.g., for first-line vs. second-line treatment) or modified indications (e.g., 
adjunctive treatment vs. monotherapy) were still considered to be conducted in approved areas.(16) For 
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each agent, we counted the number of studies conducted within and outside of FDA-approved indications 
and the total number of participants.  
 
Level 3: Comparison 
Among randomized controlled trials with advanced recruitment status conducted within initially 
approved indications, we separated “evaluation trials” from “background trials”. “Evaluation trials” 
included placebo-controlled or head-to-head trials that evaluate the clinical benefits of agents receiving 
accelerated approval (e.g., trials comparing strategies A + B vs. B, or A vs. B, where A is the agent of 
interest, and B is either an active or inactive control/agent). “Background trials” included randomized 
controlled trials where treatment effects of agents with accelerated approval could not be isolated because 
they were used as common background (“backbone”) treatment in both arms (e.g., trials comparing 
strategies A + B vs. A, or A + B vs. A + C, where A is the agent of interest, and B and C are other agents). 
We also considered trials comparing the effectiveness of different treatment sequences as background 
trials, since the effect of agents receiving accelerated approval could not be isolated in such trials. We 
counted for each agent the total number of “evaluation” and “background” trials and the total number of 
participants included.  
 
Evaluation of time lag  
We plotted and visually inspected the start dates and durations of identified randomized controlled 
trials. For each agent, we then used descriptive statistics to examine the similarity in start dates of trials 
conducted in therapeutic areas receiving initial accelerated approval and those conducted in other areas. 
In a similar fashion, we evaluated whether there was any detectable time lag between the “evaluation” and 
“background” trials for each agent. For both sets of comparisons, we first used t-tests at the drug level to 
statistically evaluate the differences in trial start dates between the two sets of studies that did or did not 
evaluate approved indications and (2) were or were not designed to evaluate the drug’s effectiveness. We 
then inspected the variability in average time lag across different therapeutic agents using the I2 measure. 
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Point estimate of I2 describes the percentage of the observed variability that is due to heterogeneity rather 
than chance.(33) I2 over 50% is conventionally considered to indicate large heterogeneity.  
 We performed meta-analyses to quantify the magnitude of mean time lags across all agents. We 
adopted the Hartung-Knapp-Sidik-Jonkman method to perform random-effects meta-analyses(34, 35) 
since it outperforms other common random-effects methods.(36) We report mean differences and 95% 
confidence intervals (CIs). Statistical analyses were performed in STATA version 14 (StataCorp). Two-
tailed p values <0.05 were considered statistically significant.  
 
 
 
Results 
Overview of approved agents and their clinical studies 
FDA granted accelerated approval to 37 novel therapeutic agents between 2000 and 2013. During 
this period, 2 to 4 new therapeutic agents per year entered the market in the accelerated approval pathway. 
Oncological and anti-viral agents accounted for four fifths of accelerated approvals during this period 
(Figure 1).  
Figure 2 shows the three levels of our review and the flow of identified records in the study. Our 
search on Clinicaltrials.gov yielded 8,951 records, corresponding to 7,757 individual studies (excluding 
duplicates) of agents granted accelerated approval. In total, there were 1,258,315 participants included in 
these studies. We observed significant variation in the number of studies per accelerated approval agent, 
ranging from 18 (for omacetaxine mepesuccinate) to 1,417 (for oxaliplatin). Most agents (23 agents; 62.2%) 
had 100 or more study records and six agents (16.2%) had 500 or more.   
Most identified studies were very small, with 5,469 studies (70.5% of total) including 100 or fewer 
participants. For 9 agents, studies with <100 participants accounted for >80% of all available studies. Only 
502 studies (6.47% of total) included 500 or more participants.  
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Level 1: Study design 
We categorized approximately one third (n=2,995) of identified records as randomized controlled 
trials, corresponding to 2,476 individual studies after removing duplicates (Figure 2). The number of 
randomized controlled trials ranged from 1 for omacetaxine mepesuccinate to 536 for oxaliplatin; five 
agents had fewer than 10 randomized studies while 10 agents had 100 trials or more (Table 1). Overall, 
681,834 participants (45.5%) were included in randomized controlled trials; the number of participants in 
randomized trials ranged from 680 for pralatrexate to 200,763 for oxaliplatin. Proportions of participants 
included in randomized controlled trials ranged from 30.6% for cetuximab to 91.2% for natalizumab 
(Table 1).  
 
Level 2: Condition  
Of 1,631 randomized controlled trials with advanced recruitment status, 906 (55.5%) were 
conducted in therapeutic areas for which agents received initial FDA accelerated approval; 202 trials 
(12.4%) were in supplemental indications; and 523 (32.1%) were in unapproved indications (Figure 2). 
The number of available trials in initially approved areas varied considerably across agents, ranging from 
1 for omacetaxine mepesuccinate and ponatinib to 183 for oxaliplatin. As shown in Table 1, trials in initial 
and supplemental indications accounted for 50% or less of all randomized controlled trials for nine agents 
receiving accelerated approval. For seven agents, all available randomized controlled trials were in 
therapeutic areas for which the agents received initial accelerated approval.  
 In total, trials conducted in initially approved areas included 390,995 participants (70.0% of total); 
trials in supplemental indications included 52,761 participants (9.5%). Taken together, these participants 
accounted for less than 50.0% of total trial populations for three accelerated approval agents: alemtuzumab 
(969; 11.9%), clofarabine (405; 11.5%), and deferiprone (526; 18.9%) (Table 1).  
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Level 3: Comparison 
The majority (495/906; 54.6%) of randomized controlled trials conducted in initially approved 
indications did not evaluate the effectiveness of accelerated approval agents in these indications (i.e., 
“background” trials). The remaining 411 (45.4%) were “evaluation” trials, testing the effectiveness of 
accelerated approval agents in FDA-approved indications. The number of available evaluation trials per 
agent ranged from 0 to 64, with over 50 evaluation trials identified for lopinavir-ritonavir and raltegravir 
used to treat HIV (Table 1). While all available randomized controlled trials for five accelerated approval 
agents evaluated their effectiveness, there were no evaluation trials for two agents (clofarabine and 
omecatexate).  
 Overall, 176,133 participants (45.5% of total) were included in randomized trials designed to test 
the effectiveness of agents granted accelerated approval. The total number of individuals participating in 
evaluation trials ranged from 0 to 24,700 (Table 1). The share of participants in evaluation trials accounted 
for less than half of the total population for 11 agents.  
 
Breakdown of cumulative evidence available on each agent 
Figure 3 summarizes the findings of the three levels of our review for each therapeutic agent. 
Despite the significant variation in the total number of studies and sample sizes for each agent, a broadly 
consistent pattern emerged about the relative distribution of available evidence as we restricted our sample 
from all identified studies to randomized controlled trials evaluating the effectiveness of accelerated 
approval agents in initially approved indications. Only a small proportion of evidence available on novel 
therapeutic agents granted accelerated approval had randomized study designs (median: 26.0%; range: 5.6-
64.3%); randomized controlled trials in initially approved indications accounted for a median proportion 
of 10.6% of all available evidence (range: 0.6-36.4%); and randomized controlled trials evaluating the 
effectiveness of accelerated approval agents in initially approved indications accounted for a median 
proportion of 6.1% (range: 0.0-20.0%) of all available evidence.  
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Evaluation of time lag: comparing FDA-approved and other indications 
Of 27 agents for which multiple randomized controlled trials conducted both within and outside 
of initially approved indications were available, we observed similar starting dates for 18 agents. When we 
meta-analyzed the difference in start times between randomized trials that did or did not evaluate approved 
indications, we found no overall difference in average start times across all agents (mean difference=-0.34, 
95% CI: -0.95 to 0.27) (Figure 4). There was high between-agent heterogeneity in mean time lags 
(I2=72.1%). Only 4 agents (deferiprone, etravirine, deferasirox, oxaliplatin) had a time lag of 2 years or 
more.  For gefitinib, randomized controlled trials in initially approved indications started on average 3.54 
years later than those in other areas (95% CI: 2.18 to 4.90). 
 
Evaluation of time lag: comparing “evaluation” and “background” trials 
When we compared the average start times of “evaluation” and “background” trials conducted 
within initially approved indications for the 25 accelerated approval agents for which both sets were 
available, the summary time lag was -1.52 years (95% CI: -2.17 to -0.87) with substantial between-agent 
heterogeneity (I2=52.5%) (Figure 5). 23 of 25 agents had on average earlier start dates for “evaluation” 
trials than “background” trials. However, only 9 agents had a time lag of at least 2 years. Trials evaluating 
the effectiveness of gemtuzumab started on average 2.18 years (95% CI: 0.34 to 4.02) later than trials using 
it as background treatment.   
 
Trajectory of evidence for each agent 
Table 2 summarizes the trajectory of available evidence for each therapeutic agent, combining all 
three elements of the findings: availability, characteristics, and timing of studies. Although most accelerated 
approval agents had two or more randomized controlled trials in initially approved indications, only two 
agents (oxaliplatin and tenofovir) had studies evaluating their effectiveness in approved indications before 
studies testing them either in other indications or as background therapies were conducted.  
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Discussion 
In this study, we systematically evaluated the existing clinical studies of novel therapeutic agents 
given accelerated approval by the FDA between 2000 and 2013. Our review identified a very large number 
of studies including over a million participants across several therapeutic areas. However, only a small 
fraction of these studies were randomized controlled trials; a sizeable proportion of randomized evidence 
was generated in therapeutic areas outside of the FDA approval; and most randomized controlled trials 
including accelerated approval agents did not evaluate their clinical benefits, but used them instead as 
common backbone treatments. Randomized controlled trials in approved vs. non-approved indications 
started on average at the same time and randomized trials evaluating the effectiveness of  agents granted 
accelerated approval started on average 1.5 years before trials using them as background treatment.  
Pharmaceutical and biotechnology companies often cite difficulties in recruiting adequate numbers 
of patients as the primary reason for failing to conduct large randomized controlled trials to evaluate the 
clinical effectiveness of accelerated approval agents in a timely manner.(17) Patients might be unwilling to 
participate in clinical studies after an agent is “reasonably likely” to be superior to available therapies. It 
may also be difficult to achieve large sample sizes due to small patient populations in some rare disease 
areas.(37) Despite these enrollment-related concerns, our findings show that very large numbers of 
patients often participate in randomized controlled trials of varying sizes both within and outside of 
initially approved therapeutic areas. Therefore, large mega-trials with these agents might have been 
feasible, if a portion of these participants could have been funneled to such efforts.(38-40) Currently, the 
thousands of clinical studies that are performed on these agents comprise mostly small investigations with 
a substantial proportion of non-randomized studies. These small and non-randomized studies offer at best 
questionable evidence on agents with accelerated approval.(41) The scientific value of such small and non-
randomized studies compared to their value as marketing tools or seeding trials to propagate their use 
should be investigated in future studies.(42)   
Perhaps unsurprisingly, accelerated approvals change the calculus of investments on additional 
research on new agents. Manufacturer sponsors may have a reduced sense of urgency to generate 
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meaningful evidence on clinical effectiveness once products receive accelerated approval.(10) They may 
not wish to risk unfavorable trial findings or even withdrawal from the market due to demonstrated lack 
of clinical effectiveness. Therefore, accelerated approval – allowing companies to market their products 
sooner and with less research expenditure – may serve as a disincentive to conduct additional research in 
therapeutic areas for which FDA granted initial approval.(10, 43)  
Indeed, our findings suggest that novel therapeutic agents receiving accelerated approval are often 
tested concurrently in several therapeutic areas, potentially to seek approval in multiple indications and 
extend market share.(19) Overall, there was no major time lag between the start dates of trials testing the 
effectiveness of accelerated approval agents in initially approved indications and trials testing them in 
supplemental indications and unapproved conditions, although there was also some diversity across 
agents.   
Even when we focused on randomized controlled trials conducted in initially approved indications, 
most were not designed to evaluate accelerated approval agents vs. comparators. Instead, accelerated 
approval agents were more likely to be included as part of background therapies. Ideally, trials 
demonstrating the effectiveness of novel agents should be available before they are widely tested and used 
as part of standard treatment algorithms.(31) However, no substantial time lag was apparent for many 
agents in our sample and the average time lag was only 1.52 years. There appears to be a tendency for 
therapeutic agents receiving accelerated approval to quickly become an integral component of standard 
treatment, despite potential shortcomings in their evidence base. 
The speed with which accelerated approval agents are embraced by the research community may 
reflect the perceived pace of innovation in drug development. However, using accelerated approval agents 
as common backbone treatment while separate trials are concurrently evaluating their effectiveness raises 
important questions about the efficiency of the research enterprise.(44) The obvious risk of this research 
strategy is that the latter group of trials may find no demonstrable therapeutic benefit of accelerated 
approval agents. Indeed, several agents initially granted accelerated approval were later found to be 
ineffective when tested in large randomized controlled trials. For example, gemtuzumab, originally 
Preprint of article accepted for publication in The Milbank Quarterly © 2017 The Milbank Memorial Fund. 
	
	 17 
approved for the treatment of acute myeloid leukemia in May 2000 under the FDA’s accelerated approval 
program, was withdrawn from the market in 2010 when its confirmatory post-approval trial showed no 
clinical benefit.(45) While it was still on the market, gemtuzumab was used as a background therapy in 
several trials, and these trials generally started earlier than those evaluating its effectiveness.  
This study has some limitations. Our sample consisted of agents approved as early as 2000. The 
trials of these agents may have incomplete or inconsistent data elements in Clinicaltrials.gov. Although 
trial sponsors and investigators often retrospectively enter information on ongoing trials, we may have 
missed randomized controlled trials if they were not registered in Clinicaltrials.gov or if they had missing 
enrollment numbers. However, limiting our analysis to 16 agents approved after 2007 yielded largely 
similar inferences (not shown). In addition, Clinicaltrials.gov may have inadequate detail about the disease, 
disorder, syndrome, or illness for each clinical study. Our categorization of identified studies according to 
condition was therefore conservative and we considered all randomized controlled trials conducted in 
expanded, modified or new indications as within approved therapeutic areas.   
FDA mandates post-approval confirmatory trials to be completed by industry sponsors to 
demonstrate clinical benefit. In our study, we did not differentiate between the clinical studies conducted 
before or after the required post-approval confirmatory trials were completed and published. FDA’s 
evidence standards are increasingly flexible and the completion of confirmatory trials may not always 
provide definitive evidence of therapeutic benefit. According to a recent systematic evaluation of 
accelerated approvals of oncology products, FDA accepted data from single-arm (non-randomized, non-
comparative) studies as sufficient evidence to grant regular approval to two agents that originally received 
accelerated approval (14) – a clear deviation from conventional regulatory requirements for market entry. 
(2) Holding all agents to the same standard, we find that only two out of 37 accelerated approval agents 
had acceptable evidence trajectories – timely availability of randomized controlled trials evaluating their 
effectiveness in initially approved indications – that would meet the information needs of patients, 
physicians, researchers, and other decision makers in the health care system.   
Taken together, our findings highlight the potential consequences of FDA accelerated approval 
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decisions on the patterns and dynamics of evidence generation on novel therapeutic agents. Lack of 
interested participants cannot be raised as an argument against performing large-scale pragmatic trials to 
rigorously test these agents for major, patient-relevant clinical outcomes. The current research landscape 
is inefficient and fragmented with thousands of small and non-randomized studies that provide 
questionable value. Accelerated approval on the basis of non-established surrogate measures may be 
perceived as full regulatory endorsement for new agents, sending a strong signal to patients, physicians, 
and researchers regarding a novel therapeutic agent’s innovative value, safety and effectiveness, in turn 
influencing the evolution and nature of scientific evidence on agents.  
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Figures and tables 
 
Figure 1. Novel therapeutic agents granted accelerated approval from 2000 to 2013 according to 
therapeutic area.  
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Figure 2. Flow of identified Clinicaltrials.gov records in the study according to three levels of review. 
 
 
Note: Total number of records at each level of the review may include duplicates; trials including more than one accelerated approval agent is counted separately for 
each therapeutic agent. Numbers in parentheses refer to the total number of studies without any duplicates.  RCT: randomized controlled trial. 
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Table 1. Total number and distribution of clinical studies and study participants for each agent according to three levels of review.  
 Identified studies 
 
Level 1: 
Availability of randomized 
controlled trials 
 
Level 2: 
Availability of randomized 
controlled trial in FDA-approved 
indication 
Level 3: 
Availability of randomized 
controlled trial evaluating agent’s 
effectiveness 
Accelerated 
approval agents 
Total number of 
clinical studies 
identified 
Number of 
participants 
included 
Number of 
randomized 
trials (%) 
Number of 
participants 
(%) 
Number of 
trials (%) 
Number of 
participants 
(%) 
Number of 
"evaluation" 
trials (%) 
Number of 
participants 
(%) 
Agalsidase 36 11,437 7 (19.4) 10,541 (92.2) 4 (100.0) 193 (100.0) 4 (100.0) 193 (100.0) 
Alemtuzumab 326 26,962 59 (18.1) 16,136 (59.8) 8 (20.0) 969 (11.9) 7 (87.5) 923 (95.3) 
Bedaquiline 28 6,594 18 (64.3) 2,661 (40.4) 6 (50.0) 781 (77.0) 4 (66.7) 436 (55.8) 
Bortezomib 804 79,503 168 (20.9) 35,936 (45.2) 67 (59.3) 22,388 (78.8) 28 (41.8) 7,462 (33.3) 
Brentuximab 107 9,256 16 (14.9) 4,096 (44.3) 6 (100.0) 685 (100.0) 3 (50.0) 491 (71.7) 
Carfilzomib 121 11,882 17 (14.0) 6,076 (51.1) 6 (87.5) 2,996 (98.9) 4 (66.7) 2,918 (97.4) 
Cetuximab 750 102,336 257 (34.3) 31,333 (30.6) 75 (42.4) 29,870 (57.3) 41 (54.7) 24,700 (82.7) 
Clofarabine 156 18,312 21 (13.5) 5,728 (31.3) 1 (10.0) 405 (11.5) 0 (0.0) 0 (0.0) 
Crizotinib 102 23,216 24 (23.5) 17,116 (73.7) 9 (64.3) 1,997 (94.7) 5 (55.6) 1,227 (61.4) 
Darunavir 206 65,040 112 (54.4) 40,580 (62.4) 64 (73.6) 17,350 (91.3) 24 (37.5) 6,931 (39.9) 
Deferasirox 90 11,339 25 (27.8) 8,391 (74.0) 10 (35.7) 1,000 (48.9) 8 (80.0) 1,746 (95.6) 
Deferiprone 57 7,345 35 (61.4) 2,082 (28.3) 7 (29.2) 526 (18.9) 4 (57.1) 233 (44.3) 
Eltrombopag 102 8,614 33 (32.4) 3,922 (45.5) 8 (30.8) 736 (20.5) 8 (100.0) 736 (100.0) 
Enfuvirtide 67 7,294 30 (44.8) 3,718 (50.9) 21 (77.8) 2,956 (91.6) 11 (52.4) 863 (30.0) 
Etravirine 79 18,824 32 (40.5) 14,142 (75.1) 19 (67.9) 3,680 (92.4) 14 (73.7) 2,777 (75.5) 
Gefitinib 366 55,600 118 (32.2) 28,174 (50.7) 47 (58.8) 16,934 (80.3) 35 (74.5) 12,793 (77.9) 
Gemtuzumab 73 15,908 19 (26.0) 5,757 (36.2) 13 (100.0) 6,759 (100.0) 11 (84.6) 6,490 (96.0) 
Ibritumomab 105 10,615 17 (16.2) 7,526 (70.9) 10 (100.0) 1,446 (100.0) 8 (80.0) 1,432 (99.0) 
Ibrutinib 165 25,195 27 (16.4) 18,019 (71.5) 2 (14.3) 804 (17.9) 2 (100.0) 804 (100.0) 
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 Identified studies 
 
Level 1: 
Availability of randomized 
controlled trials 
 
Level 2: 
Availability of randomized 
controlled trial in FDA-approved 
indication 
Level 3: 
Availability of randomized 
controlled trial evaluating agent’s 
effectiveness 
Accelerated 
approval agents 
Total number of 
clinical studies 
identified 
Number of 
participants 
included 
Number of 
randomized 
trials (%) 
Number of 
participants 
(%) 
Number of 
trials (%) 
Number of 
participants 
(%) 
Number of 
"evaluation" 
trials (%) 
Number of 
participants 
(%) 
Imatinib 631 82,090 132 (20.9) 50,049 (60.9) 36 (37.9) 9,776 (47.5) 24 (66.7) 7,433 (76.0) 
Lenalidomide 696 82,986 161 (23.1) 35,899 (43.3) 7 (6.9) 1,163 (3.5) 5 (71.4) 872 (75.0) 
Lopinavir 365 109,939 210 (57.5) 52,313 (47.6) 133 (75.1) 43,016 (84.0) 64 (48.1) 16,615 (40.2) 
Maraviroc 140 20,631 69 (49.3) 9,708 (47.1) 42 (73.7) 7,584 (86.2) 28 (66.7) 5,657 (74.6) 
Natalizumab 95 67,003 27 (28.4) 61,079 (91.2) 14 (73.7) 4,230 (81.1) 13 (92.9) 4,088 (96.6) 
Nelarabine 23 4,154 2 (8.7) 1,534 (36.9) 1 (100.0) 1,900 (100.0) 1 (100.0) 1,900 (100.0) 
Nilotinib 167 26,758 33 (19.8) 19,316 (72.2) 10 (47.6) 2,258 (64.1) 6 (60.0) 2,136 (94.6) 
Ofatumumab 114 12,450 28 (24.6) 4,145 (33.3) 8 (44.4) 2,641 (61.2) 7 (87.5) 2,371 (89.8) 
Omecatexine 18 903 1 (5.6) 898 (99.4) 1 (100.0) 5 (100.0) 0 (0.0) 0 (0.0) 
Oxaliplatin 1417 257,595 536 (37.8) 56,832 (22.1) 183 (69.3) 99,762 (87.0) 36 (19.7) 23,378 (23.4) 
Panitumumab 198 28,500 64 (32.3) 11,010 (38.6) 21 (50.0) 7,695 (68.2) 12 (57.1) 6,994 (90.9) 
Pomalidomide 110 10,977 27 (24.5) 6,373 (58.1) 8 (53.3) 1,414 (65.5) 5 (62.5) 920 (65.1) 
Ponatinib 30 3,177 4 (13.3) 1,720 (54.1) 1 (100.0) 307 (100.0) 1 (100.0) 307 (100.0) 
Pralatrexate 29 1,388 5 (17.2) 708 (51.0) 4 (80.0) 786 (79.6) 2 (50.0) 137 (28.6) 
Raltegravir 297 49,113 153 (51.5) 24,253 (49.4) 89 (78.1) 18,701 (94.0) 55 (61.8) 15,439 (82.6) 
Tenofovir 716 234,714 436 (60.9) 82,261 (35.0) 212 (66.0) 71,525 (67.5) 38 (17.9) 12,098 (17.2) 
Tipranavir 82 13,849 32 (39.0) 8,921 (64.4) 17 (56.7) 3,455 (83.5) 7 (41.2) 1,185 (34.3) 
Treprostinil 83 13,997 40 (48.2) 10,402 (74.3) 13 (56.5) 1,476 (77.0) 9 (69.2) 1,448 (98.1) 
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Figure 3. Relative availability of evidence in three levels of review for each agent.    
 
 
Note: Orange bars show the relative availability of randomized controlled trials as a subset of all clinical studies. 
Grey bars show the availability of randomized controlled trials in initially approved indications as a subset of all 
clinical studies. Yellow bars show the availability randomized controlled trials evaluating the effectiveness of 
accelerated approval agents (“evaluation” trials) relative to all available studies.   
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Figure 4. Meta-analysis of mean time lags for each agent, comparing the start times between trials that 
were and were not conducted within initially approved indications.  
 
Note: WMD: weighted mean difference; CI: confidence interval; I-sq refers to the proportion of observed variability 
that is attributable to heterogeneity rather than chance.  
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Figure 5. Meta-analysis of mean time lags for each agent, comparing the start times between trials that 
were and were not designed to test the effectiveness of therapeutic agents receiving accelerated approval.  
 
 
Note: WMD: weighted mean difference; CI: confidence interval; I-sq refers to the proportion of observed variability 
that is attributable to heterogeneity rather than chance.  
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”evaluation” trials
Earlier start time for 
”background” trials
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Table 2. Evidence trajectory for each therapeutic agent.  
 
Accelerated approval 
agent 
(1) 
Availability of 2 or 
more randomized 
controlled trials 
(2) 
Availability of 2 or 
more randomized 
controlled trials in 
FDA-approved 
indications 
(3) 
Availability of 2 or 
more “evaluation” 
trials 
(4) 
No time lag between 
trials conducted 
within and outside 
FDA-approved 
indications 
(5) 
No time lag between 
“evaluation” and 
“background” trials 
Agalsidase ü ü ü Not enough data Not enough data 
Alemtuzumab ü ü ü û Not enough data 
Bedaquiline ü ü ü û ü 
Bortezomib ü ü ü û ü 
Brentuximab ü ü ü Not enough data û 
Carfilzomib ü ü ü Not enough data ü 
Cetuximab ü ü ü û û 
Clofarabine ü û û Not enough data Not enough data 
Crizotinib ü ü ü ûû û 
Darunavir ü ü ü û ü 
Deferasirox ü ü ü û Not enough data 
Deferiprone ü ü ü ü û 
Eltrombopag ü ü ü û Not enough data 
Enfuvirtide ü ü ü û û 
Etravirine ü ü ü ü û 
Gefitinib ü ü ü ûû ü 
Gemtuzumab ü ü ü Not enough data ûû 
Ibritumomab ü ü ü Not enough data û 
Ibrutinib ü ü ü ü Not enough data 
Imatinib ü ü ü û û 
Lenalidomide ü ü ü û û 
Lopinavir ü ü ü ü ü 
Maraviroc ü ü ü û û 
Natalizumab ü ü ü û Not enough data 
Nelarabine ü û û Not enough data Not enough data 
Nilotinib ü ü ü û û 
Ofatumumab ü ü ü û Not enough data 
Omecatexine û û û Not enough data Not enough data 
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Accelerated approval 
agent 
(1) 
Availability of 2 or 
more randomized 
controlled trials 
(2) 
Availability of 2 or 
more randomized 
controlled trials in 
FDA-approved 
indications 
(3) 
Availability of 2 or 
more “evaluation” 
trials 
(4) 
No time lag between 
trials conducted 
within and outside 
FDA-approved 
indications 
(5) 
No time lag between 
“evaluation” and 
“background” trials 
Oxaliplatin ü ü ü ü ü 
Panitumumab ü ü ü û û 
Pomalidomide ü ü ü û û 
Ponatinib ü û û Not enough data Not enough data 
Pralatrexate ü ü ü Not enough data Not enough data 
Raltegravir ü ü ü ü û 
Tenofovir ü ü ü ü û 
Tipranavir ü ü ü û ü 
Treprostinil ü ü ü û ü 
 
Notes:  
ü indicates availability of two or more randomized controlled trials in columns 1-3; indicates statistically significant time lag in columns 4-5.  
û indicates lack of at least two randomized controlled trials in columns 1-3; indicates lack of statistically significant time lag in columns 4-5.  
ûû indicates statistically significant time lag with trials outside of approved indications (column 4) and “background” trials starting earlier (column 5).   
Not enough data suggests that there were not sufficient numbers of studies to estimate time lag.  
